Diminished Erk 1/2 and p38 mapk phosphorylation in skeletal muscle during sepsis

Shock

Volumn 22, Issue 6, 2004, Pages 548-554

  Vary, Thomas C ^a   Deiter, Gina ^a   Lang, Charles H ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

eIF4E; Erk 1 2 MARK; p38 MAPK; Translation initiation; Tumor necrosis factor

Indexed keywords

INITIATION FACTOR 4E; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME REGULATION; INFLAMMATION; MALE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; RAT; RNA TRANSPORT; SEPSIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT REDUCTION;

ANIMALS; EUKARYOTIC INITIATION FACTOR-4E; INFLAMMATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SKELETAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEPSIS; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 9644260647     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000144131.13900.ff<     Document Type: Article

References (47)

1. Conference ACoCP-SoCCMC: Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 20:864-875, 1992.
2. Wilmore DW: Metabolic response to severe surgical illness: Overview. World J Surg 24:705-711, 2000.
3. Plank LD, Connolly AB, Hill AG: Sequential changes in the metabolic response in severely septic patients during the first 23 days after onset ol' peritonitis. Ann Surg 228:146-158, 1998.
4. Cooney RN, Kimball SR, Vary TC: Regulation of skeletal muscle protein turnover during sepsis: Mechanisms and mediators. Shock 7:1-16, 1998.
5. Vary TC: Regulation of skeletal muscle protein turnover in sepsis. Curr Opin Clin Nutr Metab Care 1:217-224, 1998.
6. Vary TC, Kimball SR: Sepsis-induced changes in protein synthesis: differential effects on fast- and slow-twitch muscles. Am J Physiol Cell Physiol 262: C1513-C1519, 1992.
7. Jurasinski CV, Kilpatrick L, Vary TC: Amrinone prevents muscle protein wasting during chronic sepsis. Am J Physiol Endocrinol Metab 268:E491-E500, 1995.
8. Cooney R, Owens E, Jurasinski C, Gray K, Vannice J, Vary T: Interleukin-1 receptor antagonist prevents sepsis-induced inhibilion of protein synthesis. Am J Physiol Endocrinol Metab 267:E636-E641, 1994.
9. Svanberg E, Frost RA, Lang CH, Isgaard J, Jefferson LS, Kimball SR, Vary TC: IGF-I/IGFBP-3 binary complex modulates sepsis induced inhibition of protein synthesis in skeletal muscle. Am J Physiol Endocrinol Metab 279:E1145-E1158, 2000.
10. Voisin L, Gray K, Flowers KM, Kimball SR, Jefferson LS, Vary TC: Altered expression of eukaryotic initiation factor 2B in skeletal muscle during sepsis. Am J Physiol Endocrinol Metab 270:E43-E50, 1996.
11. Vary TC, Voisin L, Cooney RN: Regulation of peptide-chain initiation during sepsis by interleukin-1 receptor antagonist. Am J Physiol Endocrinol Metab 271:E309-E316, 1996.
12. Vary TC, Jurasinski CV, Kimball SR: Reduced 40S initiation complex formation in skeletal muscle during sepsis. Mol Cell Biochem 178:81-86, 1998.
13. Raught B, Gingras A-C: eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol 31:43-57, 1999.
14. Rhoads RE: Regulation of eukaryotic protein synthesis by initiation factors. J Biol Chem 268:3017-3020, 1993.
15. Rhoads RE, Joshi-Barve S, Minich WB: Participation of initiation factors in recruitment of mRNA to ribosomes. Biochimie 76:831-838, 1994.
16. Sonenberg N: Regulation of translation and cell growth by eIF-4E. Biochimie 76:839-846, 1994.
17. Jurasinski CV, Gray K, Vary TC: Modulation of skeletal muscle protein synthesis by amino acids and insulin during sepsis. Metabolism 44:1130-1138, 1995.
18. Vary TC, Kimball SR: Effect of sepsis on eIF4E availability in skeletal muscle. Am J Physiol Endocrinol Metab 279:E1178-E1184, 2000.
19. Vary TC, Jefferson LS, Kimball SR: Insulin fails to stimulate muscle protein synthesis in sepsis despite unimpaired signaling to 4E-BP1 and S6K1. Am J Physiol Endocrinol Metab 281:E1045-E1053, 2001.
20. Vary TC, Deiter G, Kimball SR: Phosphorylation of eukaryotic initiation factor eIF2Bε in skeletal muscle during sepsis. Am J Physiol Endocrinol Metab 283: E1032-E1039, 2002.
21. Vary TC, Owens E, Beers JK, Verner K, Cooney R: Sepsis inhibits synthesis of myofibrillar and sarcoplasmic proteins: Modulation by interleukin-1 receptor antagonist. Shock 6:13-18, 1996.
22. Vary TC, Hazen SA, Maish G III, Cooney R: TNF binding protein prevents hyperlactatemia and inactivation of PDH complex in skeletal muscle during sepsis. J Surg Res 80:44-51, 1998.
23. Cooney RN, Kimball SR, Eckman R, Maish G III, Shumate M, Vary TC: TNF-binding protein ameliorates inhibition of skeletal muscle protein synthesis during sepsis. Am J Physiol Endocrinol Metab 276:E611-E619, 1999.
24. Hale KK, Smith CG, Baker SL, Vanderslice RW, Squires CH, Gleason TM, Tucker KK, Kohno T, Russell DA: Multifunctional regulation of the biological effects of TNF-α by soluble type I and type II TNF receptors. Cytokine 7:26-38, 1995.
25. Espat NJ, Cenden JC, Bierle EA, Auffenberg TA, Rosenberg J, Russell DA, Kenney JS, Fischer E, Montegut W, Lowery SF, Copeland EM III, Moldawer LL: PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res 59:153-168, 1995.
26. Cooney R, Iocono J, Maish G III, Smith JS, Ehrlich P: Tumor necrosis factor mediates impaired wound healing in chronic abdominal sepsis. J Trauma 42: 415-420, 1997.
27. Russell DA, Tucker KK, Chinookoswong N, Thompson R, Kohno T: Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function. J Infect Dis 171:1528-1538, 1995.
28. Solorzano C, Kaibara A, Hess PJ, Edwards PD, Ksontini R, Abouhamze A, MacDaniel S, Frazier J, Trujillo D, Kieft G, Seely J, Kohno T, Cosenza ME, Clare-Slalzer M, MacKay SLD, Martin SW, Moldawer LL, Edwards CK: Pharmacokinetics, immunogenicity and efficiency of dimeric TNFR binding proteins in healthy and bacteremic baboon. J Appl Physiol 84:1119-1130, 1998.
29. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43-52, 1992.
30. Lang CH, Frost RA, Nairn AC, MacLean DA, Vary TC: TNFα impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 282:E336-E347, 2002.
31. Fan J, Bagby GJ, Gelato MC, Lang CH: Regulation of insulin-like growth factor-I content and IGF-binding proteins by tumor necrosis factor. Am J Physiol 269:R1204-R1212, 1995.
32. Kimball S, Jurasinski C, Lawrence J Jr, Jefferson L: Insulin stimulates protein synthesis in skeletal muscle by enhancing the association of eIF-4E and eIF-4G. Am J Physiol Cell Physiol 272:C754-C759, 1997.
33. Yoshizawa F, Kimball SR, Vary TC, Jefferson LS: Effect of dietary protein on translation initiation in rat skeletal muscle and liver. Am J Physiol 275:E814-E820, 1998.
34. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89:4845-4849, 1992.
35. Vary TC: Interorgan protein and carbohydrate metabolic relationships during sepsis: Necessary evils or uncanny coincidences? Curr Opin Clin Nutr Metab Care 2:235-242, 1999.
36. Minich WB, Balasta ML, Goss DJ, Rhoads RE: Chromatographic resolution of in vivo phosphorylated and nonphosphorylated eukaryotic initiation factor eIF-4E: increased cap affinity of the phosphorylated form. Proc Natl Acad Sci USA 91: 7668-7672, 1994.
37. Duncan R, Milburn SC, Hershey JWB: Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects. J Biol Chem 262: 380-388, 1987.
38. Vary TC, Dardevet D, Voisin L, Grizard J, Buffiere C, Denis P, Brueille D, Obled C: Pentoxifylline improves insulin action limiting skeletal muscle catabolism following infection. J Endocrinol 163:15-24, 1999.
39. Roth J, Martin D, Storr B, Zeisberger E: Neutralization of pyrogen-induced tumour necrosis factor by its type 1 soluble receptor in guinea-pigs: effects on fever and interleukin-6 release. J Physiol 509:267-275, 1990.
40. Fattori E, Cappelleti M, Costa P, Sellito C, Canton L, Carelli M, Faggioni R, Fantuzzi G, Ghenzi P, Poli V: Defective inflammatory response in interleukin-6 deficient mice. J Exp Med 180:1243-1250, 1993.
41. Cooney RN, Maish GO III, Gilpin T, Shumate ML, Lang CH, Vary TC: Mechanism of IL-1 induced inhibition of protein synthesis in skeletal muscle. Shock 11:235-241, 1999.
42. Smith HL, Tisdale MJ: Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes. Br J Cancer 89:1783-1788, 2003.
43. Frost RA, Lang CH, Gelato MC: Transient exposure of human myoblasts to tumor necrosis factor-α inhibits serum and insulin-like growth-factor-I stimulated protein synthesis. Endocrinology 138:4153-4159, 1997.
44. Ishida M, Ishida T, Nakashima H, Miho N, Miyagawa K, Chayama K, Oshima T, Kambe M, Yoshizumi M: Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle. Circ Res 93:1218-1224, 2003.
45. Kellerer RJ, Govindarajan A, Jung HY, Kang H, Tonegawa S: Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 116:467-479, 2004.
46. Klejin M, Proud CG: The regulation of protein synthesis and translation factors by CD3 and CD28 in human primary T lymphocytes. BMC Biochem 3:11, 2002.
47. Yamagiwa Y, Marienfeld C, Tadlock L, Patel T: Translational regulation by p38 mitogen-activated protein kinase signaling during huamn cholangiocarcinoma growth. Hepatology 38:158-166, 2003.